Skip to main content
Equibles
OABIW logo

OABIW · OmniAb, Inc.

Track OABIW — free

Use OABIW with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OABIW

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.05 At close · Aug 6
Market Cap
$6.56M
Shares
145.39M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.05 Open$0.05 Day$0.05–0.05 Available close range$0.05–0.08 Avg vol available · 2d15K Short int9K · 0.0% float · 3.7d Short vol47% Last earningsAug 6, 2026 DataJul 2026–Aug 2026 Filing10-Q · Aug 6

The closing range uses available history since Jul 28, 2026; less than a full year is stored.

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Limited Sentiment Bullish Fundamentals Weak Quant / Vol Limited
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      52-week position 0%
      near low
      Momentum
      relative strength
      Limited
      Not enough data for a confident read.
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Accumulating
      +1% holders QoQ · +21 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      0.01% of float · ▼ -4.5% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      142 holders — near 3-yr low, contrarian setup
      Fundamentals
      Weak
      Revenue growth −29%
      Y/Y
      EPS growth +7%
      Y/Y
      Free cash flow $-37.0M
      Balance sheet $25.5M
      net cash
      Quant / Vol
      risk profile
      Limited
      Not enough data for a confident read.

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 6, 2026
      2026
      Revenue $32M – $36M
      prior FY $18.67M midpoint +82.1% Y/Y
      Costs and operating expenses GAAP $84M – $88M
      end of the year
      Cash and cash equivalents $37M – $41M
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Revenue · 2025 $18M – $22M
      Operating expense · 2025 $82M – $86M
      Cash · end of 2025 $52M – $56M
      Guided vs delivered · last 1 settled
      Revenue 2025
      guided $18M – $22M
      $18.67M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      1 · 1 · 0
      50 / 200-day cross
      No cross Neutral
      52-week position
      0% Bearish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Accumulating
      +1% holders QoQ · +21 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      0.01% of float · ▼ -4.5% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      142 holders — near 3-yr low, contrarian setup
      Price context
      position in its available closing range
      Range low $0 Now $0 · 0% Range high $0

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cash costs and operating expenses non-GAAP $25.5M first half of 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OABIW
      OmniAb, Inc.
      this stock
      		$6.56M — -29.3% — 0.0%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      142
      % held
      42.5%
      Net QoQ
      +2.9M sh
      Top holder
      Whitefort Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      6
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      9.3K
      Days to cover
      3.7d
      Change
      -442 sh
      View
      Short Volume
      Short vol %
      47%
      As of
      Aug 13, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      100
      Value
      $12
      As of
      Jun 22, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $18.7M
      Net income (FY)
      $-64.8M
      EPS diluted
      $-0.57
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $10.6K
      Shares
      7.2K
      Filed
      Apr 7, 2026
      View
      Exempt Offerings
      Offering
      $30.0M
      Filed
      Sep 10, 2025
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Oct 6, 2026
      Last call
      Aug 6, 2026
      View
      Investor Relations
      Latest news
      OmniAb Reports Second Quarter 202…
      Published
      Aug 6, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      OABIW — — — -45.9% —
      SPY +3.6% +2.2% +12.8% +2.9% +12.7%
      vs SPY — — — -48.8% —
      Key facts CIK 1846253 CUSIP 68218J111 13F (30d) 139 filings 137 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)